Sun Pharma Advanced Research Company Share PriceSun Pharma Advanced Research Company

₹224.85
2.2 (0.99%)
As on 26 September, 2023 | 14:54 BSE: 532872 NSE: SPARCISIN: INE232I01014

Sun Pharma Advanced Research Company Performance

Day Range

  • Low 222
  • High 231.8
224.85

52 Week Range

  • Low 162.1
  • High 265.85
224.85
  • Open Price223
  • Previous Close222.65
  • Volume1201839

Start SIP in Sun Pharma Advanced Research Company

Start SIP

Sun Pharma Advanced Research Company Share Price

  • Over 1 Month 4.17%
  • Over 3 Month 18.15%
  • Over 6 Month 31.9%
  • Over 1 Year 5.2%

Sun Pharma Advanced Research Company Key Statistics

P/E Ratio -31
PEG Ratio 6.2
Market Cap Cr 7,297
Price to Book Ratio 14.2
EPS -6.9
Dividend 0
Relative Strength Index 38.37
Money Flow Index 59.08
MACD Signal 2.27
Average True Range 8.52

Sun Pharma Advanced Research Company Investment Rating

  • Master Rating:
  • Sun Pharma Advd.Resh. has an operating revenue of Rs. 234.27 Cr. on a trailing 12-month basis. An annual revenue growth of 73% is outstanding, Pre-tax margin of -93% needs improvement, ROE of -43% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -10% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 31 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Sun Pharma Advanced Research Company Financials
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2448131322825
Operating Expenses Qtr Cr 1261371159410792
Operating Profit Qtr Cr -102-9016-63-78-67
Depreciation Qtr Cr 333333
Interest Qtr Cr 003322
Tax Qtr Cr 000000
Net Profit Qtr Cr -95-8210-68-82-71
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 250144
Operating Expenses Annual Cr 453324
Operating Profit Annual in Cr -214-187
Depreciation Cr 1210
Interest Annual Cr 813
Tax Annual Cr 00
Net Profit Annual Cr -223-203
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr -69-208
Cash from Investing Activity Annual Cr -548-29
Cash from Financing Annual Activity Cr 617229
Net Cash Flow Annual Cr -1-8
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 51331
Fixed Assets Annual Cr 133118
Total Non Current Assets Annual Cr 375209
Total Current Assets Annual Cr 45571
Total Assets Annual Cr 830280
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 161
ROE Annual % -43-651
ROCE Annual % -33-175
Total Debt to Total Equity Annual --
EBDIT Annual Margin % -85-131
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Sun Pharma Advanced Research Company Technicals

EMA & SMA

Current Price
₹224.85
2.2 (0.99%)
  • Bullish Moving Average
  • ___
  • 5
  • Bearish Moving Average
  • ___
  • 11
  • 20 Day
  • ₹237.01
  • 50 Day
  • ₹231.93
  • 100 Day
  • ₹222.48
  • 200 Day
  • ₹217.73
  • 20 Day
  • ₹242.7
  • 50 Day
  • ₹234.39
  • 100 Day
  • ₹216.29
  • 200 Day
  • ₹207.09

Sun Pharma Advanced Research Company Resistance and Support

PIVOT
₹224.
Resistance
First Resistance ₹226
Second Resistance ₹229.35
Third Resistance ₹231.35
RSI 38.37
MFI 59.08
MACD Single Line 2.27
MACD -1.47
Support
First Resistance ₹220.65
Second Resistance ₹218.65
Third Resistance ₹215.3

Sun Pharma Advanced Research Company Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 285,977 10,146,464 35.48
Week 297,897 10,786,859 36.21
1 Month 2,028,175 38,717,868 19.09
6 Month 1,087,232 25,028,078 23.02

Sun Pharma Advanced Research Company Result Highlights

Sun Pharma Advanced Research Company Synopsis

NSE-Medical-Biomed/Biotech

Sun Pharma Advanced is involved in the business activities of Scientific research and development. Company’s Total Operating Revenue is Rs. 238.78 Cr. and Equity Capital is Rs. 32.45 Cr. for the Year ended 31/03/2023. Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837.
Market Cap 7,287
Sales 234
Shares in Float 11.03
No of funds 82
Yield
Book Value 14.09
U/D Vol ratio 3.1
LTDebt / Equity
Alpha 0.03
Beta 0.71

Sun Pharma Advanced Research Company

Owner NameJun-23Mar-23Jan-23Dec-22
Promoters 65.67%65.67%65.67%68.22%
Mutual Funds 0.21%0.21%0.21%0.25%
Foreign Portfolio Investors 3.64%3.64%3.54%3.48%
Financial Institutions/ Banks
Individual Investors 16.13%16.18%16.34%16%
Others 14.35%14.3%14.24%12.05%

Sun Pharma Advanced Research Company Management

Name Designation
Mr. Dilip S Shanghvi Chairman & Non-Exe.Director
Dr. T Rajamannar Non Executive Director
Dr. Robert J Spiegel Independent Director
Mr. Sudhir V Valia Non Executive Director
Ms. Bhavna Doshi Independent Director
Dr. Ferzaan Engineer Independent Director

Sun Pharma Advanced Research Company Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Sun Pharma Advanced Research Company Corporate Action

Date Purpose Remarks
2023-08-07 Quarterly Results
2023-05-22 Audited Results & Others To consider Fund Raising
2023-02-13 Quarterly Results
2022-11-07 Quarterly Results
2022-08-08 Quarterly Results & Others Inter alia, to consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.

Sun Pharma Advanced Research Company MF Shareholding

Name Amount(cr)
Quant Small Cap Fund Growth 8075
Nippon India Nifty Smallcap 250 Index Fund Reg Gr 657
Motilal Oswal Nifty 500 Fund Regular Growth 524
Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth 422
SBI Nifty Smallcap 250 Index Fund Regular Growth 281
  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Sun Pharma Advanced Research Company FAQs

What is Share Price of Sun Pharma Advanced Research Company ?

Sun Pharma Advanced Research Company share price is ₹224 As on 26 September, 2023 | 14:40

What is the Market Cap of Sun Pharma Advanced Research Company ?

The Market Cap of Sun Pharma Advanced Research Company is ₹7296.9 Cr As on 26 September, 2023 | 14:40

What is the P/E ratio of Sun Pharma Advanced Research Company ?

The P/E ratio of Sun Pharma Advanced Research Company is -31 As on 26 September, 2023 | 14:40

What is the PB ratio of Sun Pharma Advanced Research Company ?

The PB ratio of Sun Pharma Advanced Research Company is 14.2 As on 26 September, 2023 | 14:40

Q2FY23